Reported Earlier: Ligand Updates 5-Year Outlook: Long–Term Royalty Receipts Expected To Deliver At Least A 23% CAGR; Existing Commercial Programs And Late-Stage Pipeline Support Royalty Revenue CAGR Of 20%

Ligand will also provide an updated 5-year outlook:

• Long–term royalty receipts expected to deliver at least a 23% compound annual growth rate (CAGR)
• Existing commercial programs and late-stage pipeline ("Pharm Team") support royalty revenue CAGR of 20%